• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid.

作者信息

Sowerby Laura, Dewan Anna K, Granter Scott, Gandhi Leena, LeBoeuf Nicole R

机构信息

The Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.

Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.

出版信息

JAMA Dermatol. 2017 Jun 1;153(6):603-605. doi: 10.1001/jamadermatol.2017.0091.

DOI:10.1001/jamadermatol.2017.0091
PMID:28355425
Abstract
摘要

相似文献

1
Rituximab Treatment of Nivolumab-Induced Bullous Pemphigoid.利妥昔单抗治疗纳武单抗诱导的大疱性类天疱疮。
JAMA Dermatol. 2017 Jun 1;153(6):603-605. doi: 10.1001/jamadermatol.2017.0091.
2
Novel use of combination therapeutic plasma exchange and rituximab in the treatment of nivolumab-induced bullous pemphigoid.联合治疗性血浆置换和利妥昔单抗在治疗纳武单抗诱导的大疱性类天疱疮中的新应用。
Int J Dermatol. 2018 Nov;57(11):1372-1374. doi: 10.1111/ijd.13970. Epub 2018 Apr 6.
3
Bullous pemphigoid in a patient treated with nivolumab.一名接受纳武单抗治疗的患者发生大疱性类天疱疮。
Dermatol Ther. 2019 Sep;32(5):e13030. doi: 10.1111/dth.13030. Epub 2019 Aug 1.
4
Lichen planus pemphigoides developing from patient with non-small-cell lung cancer treated with nivolumab.一名接受纳武单抗治疗的非小细胞肺癌患者发生了类天疱疮样扁平苔藓。
J Dermatol. 2019 Oct;46(10):e374-e375. doi: 10.1111/1346-8138.14906. Epub 2019 May 7.
5
Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab.一名转移性恶性黑色素瘤患者在使用纳武单抗治疗失败后，因使用伊匹单抗诱发大疱性类天疱疮。
J Dermatol. 2018 Jan;45(1):e21-e22. doi: 10.1111/1346-8138.14043. Epub 2017 Sep 25.
6
A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management.一例纳武利尤单抗诱导的大疱性类天疱疮：程序性细胞死亡蛋白 1/程序性死亡配体 1 抑制剂相关皮肤毒性的综述及诊断与管理建议。
Oncologist. 2018 Oct;23(10):1119-1126. doi: 10.1634/theoncologist.2018-0128. Epub 2018 Jul 17.
7
Bullous Pemphigoid-like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature.大疱性类天疱疮样皮肤病变和明显嗜酸性粒细胞增多症在接受纳武利尤单抗治疗的黑色素瘤患者中：病例报告及文献复习。
J Immunother. 2018 Apr;41(3):164-167. doi: 10.1097/CJI.0000000000000210.
8
Severe bullous pemphigoid in a metastatic lung cancer patient treated with pembrolizumab.一名接受派姆单抗治疗的转移性肺癌患者发生严重大疱性类天疱疮。
J Dermatol. 2019 Jul;46(7):e232-e233. doi: 10.1111/1346-8138.14813. Epub 2019 Feb 13.
9
Bullous pemphigoid exacerbated by nivolumab and temporally rescued with therapeutic plasma exchange.纳武单抗加重的大疱性类天疱疮，经治疗性血浆置换暂时缓解。
J Dermatol. 2024 May;51(5):e149-e150. doi: 10.1111/1346-8138.17044. Epub 2023 Nov 27.
10
Bullous pemphigoid and nivolumab: Dermatologic management to support and continue oncologic therapy.大疱性类天疱疮与纳武单抗：支持并继续肿瘤治疗的皮肤科管理
Eur J Cancer. 2018 Nov;103:284-286. doi: 10.1016/j.ejca.2018.08.022. Epub 2018 Sep 26.

引用本文的文献

1
Skin Reactions and Other Underappreciated Dermatologic Side Effects of Cancer Therapies.癌症治疗的皮肤反应及其他未得到充分重视的皮肤科副作用
Curr Treat Options Oncol. 2025 Aug 14. doi: 10.1007/s11864-025-01333-5.
2
The Use of Biologic Agents for the Treatment of Cutaneous Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Review of Reported Cases.生物制剂在治疗免疫检查点抑制剂相关皮肤免疫相关不良事件中的应用：病例报告综述。
Am J Clin Dermatol. 2024 Jul;25(4):595-607. doi: 10.1007/s40257-024-00866-z. Epub 2024 May 20.
3
Oral Toxicities Associated with Immune Checkpoint Inhibitors: Meta-Analyses of Clinical Trials.
免疫检查点抑制剂相关的口腔毒性：临床试验的荟萃分析
J Immunother Precis Oncol. 2024 Feb 5;7(1):24-40. doi: 10.36401/JIPO-23-14. eCollection 2024 Feb.
4
Delayed Onset of Bullous Pemphigoid Secondary to Nivolumab.纳武单抗继发大疱性类天疱疮的延迟发作
Cureus. 2023 Aug 9;15(8):e43230. doi: 10.7759/cureus.43230. eCollection 2023 Aug.
5
Rituximab in steroid-refractory immune-related pancreatitis: a case report.利妥昔单抗治疗激素难治性免疫相关性胰腺炎：一例报告
Front Oncol. 2023 Jul 31;13:1205720. doi: 10.3389/fonc.2023.1205720. eCollection 2023.
6
Cutaneous Side Effects of Modern Targeted Therapy and Immunotherapy in Patients with Dermatological Malignancies.现代靶向治疗和免疫治疗对皮肤恶性肿瘤患者的皮肤副作用
Cancers (Basel). 2023 Jun 9;15(12):3126. doi: 10.3390/cancers15123126.
7
Detection of novel therapies using a multi-national, multi-institutional registry of cutaneous immune-related adverse events and management.使用多国多机构皮肤免疫相关不良反应和管理登记处来检测新型疗法。
Int J Dermatol. 2023 Aug;62(8):1020-1025. doi: 10.1111/ijd.16714. Epub 2023 May 19.
8
Biological treatment for bullous pemphigoid.大疱性类天疱疮的生物治疗。
Front Immunol. 2023 Apr 27;14:1157250. doi: 10.3389/fimmu.2023.1157250. eCollection 2023.
9
Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced Melanoma.晚期黑色素瘤患者免疫治疗的皮肤不良反应
Cancers (Basel). 2023 Mar 31;15(7):2084. doi: 10.3390/cancers15072084.
10
A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors.大疱性类天疱疮作为免疫检查点抑制剂不良反应的单机构回顾性研究经验
Cancers (Basel). 2022 Nov 5;14(21):5451. doi: 10.3390/cancers14215451.